New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
11:00 EDTAZNAstraZeneca unit says MEDI4736 studies showed clinical activity
MedImmune, the biologics research and development arm of AstraZeneca, presented results from its novel investigational immunotherapy portfolio, focusing on MEDI4736, at the American Society of Clinical Oncology meeting. "Overall, studies demonstrated durable and tolerability for MEDI4736 across a range of tumor types," the company said. In a Phase I dose-escalation study of MEDI4736 in 27 patients with advanced solid tumors, reduction of tumor burden was seen at multiple dose levels in as early as six weeks. Clinical activity was maintained for at least one year, with 19% of patients achieving a partial response and 39% of patients achieving disease control. "There was a very low frequency of drug-related serious adverse events, and no dose-limiting toxicities were observed," Medimmune added.
News For AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:51 EDTAZNRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
August 24, 2015
05:13 EDTAZNAstraZeneca to collaborate with Peregrine on cancer immunotherapy clinical trial
Subscribe for More Information
August 23, 2015
12:35 EDTAZNBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 20, 2015
11:33 EDTAZNLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
09:23 EDTAZNAdvaxis, MedImmune begin enrollment in axalimogene filolisbac Phase I/II study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use